{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T04:32:38Z","timestamp":1764390758748,"version":"3.46.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82101962"],"award-info":[{"award-number":["82101962"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"DOI":"10.1186\/s40348-025-00212-1","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T04:24:36Z","timestamp":1764390276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early-onset systemic lupus erythematosus in a patient with an inborn error of immunity caused by a NRAS mutation and treated with telitacicept"],"prefix":"10.1186","volume":"12","author":[{"given":"Zhijuan","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"issue":"10441","key":"212_CR1","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi A, Igel T, Mok CC, Arnaud L (2024) Systemic lupus erythematosus. Lancet 403(10441):2326\u20132338. https:\/\/doi.org\/10.1016\/S0140-6736(24)00398-2","journal-title":"Lancet"},{"issue":"9","key":"212_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MRW Barber","year":"2021","unstructured":"Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY et al (2021) Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 17(9):515\u2013532. https:\/\/doi.org\/10.1038\/s41584-021-00668-1","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"212_CR3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nrrheum.2010.121","volume":"6","author":"S Kamphuis","year":"2010","unstructured":"Kamphuis S, Silverman ED (2010) Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 6(9):538\u2013546. https:\/\/doi.org\/10.1038\/nrrheum.2010.121","journal-title":"Nat Rev Rheumatol"},{"key":"212_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jpeds.2018.01.045","volume":"196","author":"O Harry","year":"2018","unstructured":"Harry O, Yasin S, Brunner H (2018) Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. J Pediatr 196:22-30.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2018.01.045","journal-title":"J Pediatr"},{"issue":"8","key":"212_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/ard-2022-223741","volume":"82","author":"MK Crow","year":"2023","unstructured":"Crow MK (2023) Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis 82(8):999\u20131014. https:\/\/doi.org\/10.1136\/ard-2022-223741","journal-title":"Ann Rheum Dis"},{"key":"212_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coi.2017.10.008","volume":"49","author":"P Costa-Reis","year":"2017","unstructured":"Costa-Reis P, Sullivan KE (2017) Monogenic lupus: it\u2019s all new! Curr Opin Immunol 49:87\u201395. https:\/\/doi.org\/10.1016\/j.coi.2017.10.008","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"212_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102361","volume":"18","author":"O Omarjee","year":"2019","unstructured":"Omarjee O, Picard C, Frachette C, Moreews M, Rieux-Laucat F, Soulas-Sprauel P et al (2019) Monogenic lupus: dissecting heterogeneity. Autoimmun Rev 18(10):102361. https:\/\/doi.org\/10.1016\/j.autrev.2019.102361","journal-title":"Autoimmun Rev"},{"issue":"9","key":"212_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41581-023-00732-x","volume":"19","author":"CG Vinuesa","year":"2023","unstructured":"Vinuesa CG, Shen N, Ware T (2023) Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants. Nat Rev Nephrol 19(9):558\u2013572. https:\/\/doi.org\/10.1038\/s41581-023-00732-x","journal-title":"Nat Rev Nephrol"},{"key":"212_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.coi.2017.10.001","volume":"49","author":"F Rieux-Laucat","year":"2017","unstructured":"Rieux-Laucat F (2017) What\u2019s up in the ALPS. Curr Opin Immunol 49:79\u201386. https:\/\/doi.org\/10.1016\/j.coi.2017.10.001","journal-title":"Curr Opin Immunol"},{"issue":"21","key":"212_CR10","doi-asserted-by":"publisher","first-page":"8953","DOI":"10.1073\/pnas.0702975104","volume":"104","author":"JB Oliveira","year":"2007","unstructured":"Oliveira JB, Bid\u00e8re N, Niemela JE, Zheng L, Sakai K, Nix CP et al (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A 104(21):8953\u20138. https:\/\/doi.org\/10.1073\/pnas.0702975104","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"212_CR11","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1182\/blood-2010-07-295501","volume":"117","author":"JE Niemela","year":"2011","unstructured":"Niemela JE, Lu L, Fleisher TA, Davis J, Caminha I, Natter M et al (2011) Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood 117(10):2883\u20132886. https:\/\/doi.org\/10.1182\/blood-2010-07-295501","journal-title":"Blood"},{"issue":"10","key":"212_CR12","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1182\/blood-2010-08-301515","volume":"117","author":"M Takagi","year":"2011","unstructured":"Takagi M, Shinoda K, Piao J, Mitsuiki N, Takagi M, Matsuda K et al (2011) Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood 117(10):2887\u20132890. https:\/\/doi.org\/10.1182\/blood-2010-08-301515","journal-title":"Blood"},{"issue":"2","key":"212_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.semarthrit.2013.04.009","volume":"43","author":"B Bader-Meunier","year":"2013","unstructured":"Bader-Meunier B, Cav\u00e9 H, Jeremiah N, Magerus A, Lanzarotti N, Rieux-Laucat F, Cormier-Daire V (2013) Are rasopathies new monogenic predisposing conditions to the development of systemic lupus erythematosus? Case report and systematic review of the literature. Semin Arthritis Rheum 43(2):217\u2013219. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.04.009","journal-title":"Semin Arthritis Rheum"},{"key":"212_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.clim.2016.12.006","volume":"175","author":"RJ Ragotte","year":"2017","unstructured":"Ragotte RJ, Dhanrajani A, Pleydell-Pearce J, Del Bel KL, Tarailo-Graovac M, van Karnebeek C et al (2017) The importance of considering monogenic causes of autoimmunity: a somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus. Clin Immunol 175:143\u2013146. https:\/\/doi.org\/10.1016\/j.clim.2016.12.006","journal-title":"Clin Immunol"},{"issue":"1","key":"212_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-019-0346-1","volume":"17","author":"W Wang","year":"2019","unstructured":"Wang W, Zhou Y, Zhong L, Wang L, Tang X, Ma M et al (2019) RAS-associated autoimmune leukoproliferative disease (RALD) manifested with early-onset SLE-like syndrome: a case series of RALD in Chinese children. Pediatr Rheumatol Online J 17(1):55. https:\/\/doi.org\/10.1186\/s12969-019-0346-1","journal-title":"Pediatr Rheumatol Online J"},{"issue":"20","key":"212_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020232","volume":"99","author":"G Li","year":"2020","unstructured":"Li G, Li Y, Liu H, Shi Y, Guan W, Zhang T et al (2020) Genetic heterogeneity of pediatric systemic lupus erythematosus with lymphoproliferation. Medicine Baltimore 99(20):e20232. https:\/\/doi.org\/10.1097\/MD.0000000000020232","journal-title":"Medicine Baltimore"},{"issue":"4","key":"212_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1102140","volume":"366","author":"MJ Ombrello","year":"2012","unstructured":"Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P et al (2012) Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 366(4):330\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1102140","journal-title":"N Engl J Med"},{"issue":"6","key":"212_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10875-015-0177-x","volume":"35","author":"JD Milner","year":"2015","unstructured":"Milner JD (2015) Plaid: a syndrome of complex patterns of disease and unique phenotypes. J Clin Immunol 35(6):527\u2013530. https:\/\/doi.org\/10.1007\/s10875-015-0177-x","journal-title":"J Clin Immunol"},{"issue":"4","key":"212_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ajhg.2012.08.006","volume":"91","author":"Q Zhou","year":"2012","unstructured":"Zhou Q, Lee GS, Brady J, Datta S, Katan M, Sheikh A et al (2012) A hypermorphic missense mutation in PLCG2, encoding phospholipase C\u03b32, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet 91(4):713\u201320. https:\/\/doi.org\/10.1016\/j.ajhg.2012.08.006","journal-title":"Am J Hum Genet"},{"issue":"7","key":"212_CR20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s10875-020-00794-7","volume":"40","author":"A Mart\u00edn-Nalda","year":"2020","unstructured":"Mart\u00edn-Nalda A, Fortuny C, Rey L, Bunney TD, Alsina L, Esteve-Sol\u00e9 A et al (2020) Severe autoinflammatory manifestations and antibody deficiency due to novel hypermorphic PLCG2 mutations. J Clin Immunol 40(7):987\u20131000. https:\/\/doi.org\/10.1007\/s10875-020-00794-7","journal-title":"J Clin Immunol"},{"issue":"2","key":"212_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10875-019-00731-3","volume":"40","author":"T Novice","year":"2020","unstructured":"Novice T, Kariminia A, Del Bel KL, Lu H, Sharma M, Lim CJ et al (2020) A germline mutation in the C2 domain of PLCgamma2 associated with Gain-of-Function expands the for phenotype PLCG2-Related diseases. J Clin Immunol 40(2):267\u2013276. https:\/\/doi.org\/10.1007\/s10875-019-00731-3","journal-title":"J Clin Immunol"},{"issue":"5","key":"212_CR22","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.jaci.2023.06.020","volume":"152","author":"P Tao","year":"2023","unstructured":"Tao P, Han X, Wang Q, Wang S, Zhang J, Liu L et al (2023) A gain-of-function variation in PLCG1 causes a new immune dysregulation disease. J Allergy Clin Immunol 152(5):1292\u20131302. https:\/\/doi.org\/10.1016\/j.jaci.2023.06.020","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"212_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78(9):1151\u20131159. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214819","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"212_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030712","volume":"9","author":"E Demirkaya","year":"2020","unstructured":"Demirkaya E, Sahin S, Romano M, Zhou Q, Aksentijevich I (2020) New horizons in the genetic etiology of systemic lupus erythematosus and lupus-like disease: monogenic lupus and beyond. J Clin Med 9(3):712. https:\/\/doi.org\/10.3390\/jcm9030712","journal-title":"J Clin Med"},{"issue":"3","key":"212_CR25","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bjh.19564","volume":"205","author":"KE Sullivan","year":"2024","unstructured":"Sullivan KE, Lambert M (2024) Ras-associated autoimmune lymphoproliferative disorder. Br J Haematol 205(3):819\u2013822. https:\/\/doi.org\/10.1111\/bjh.19564","journal-title":"Br J Haematol"},{"issue":"18","key":"212_CR26","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood-2014-11-567917","volume":"125","author":"KR Calvo","year":"2015","unstructured":"Calvo KR, Price S, Braylan RC, Oliveira JB, Lenardo M, Fleisher TA, Rao VK (2015) JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. Blood 125(18):2753\u20132758. https:\/\/doi.org\/10.1182\/blood-2014-11-567917","journal-title":"Blood"},{"issue":"1","key":"212_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10875-020-00883-7","volume":"41","author":"Q Neven","year":"2021","unstructured":"Neven Q, Boulanger C, Bruwier A, de Ville de Goyet M, Meyts I, Moens L et al (2021) Clinical spectrum of Ras-Associated autoimmune leukoproliferative disorder (RALD). J Clin Immunol 41(1):51\u201358. https:\/\/doi.org\/10.1007\/s10875-020-00883-7","journal-title":"J Clin Immunol"},{"issue":"2","key":"212_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100905","volume":"297","author":"JT Jackson","year":"2021","unstructured":"Jackson JT, Mulazzani E, Nutt SL, Masters SL (2021) The role of PLC\u03b32 in immunological disorders, cancer, and neurodegeneration. J Biol Chem 297(2):100905. https:\/\/doi.org\/10.1016\/j.jbc.2021.100905","journal-title":"J Biol Chem"},{"issue":"12","key":"212_CR29","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1111\/jdv.15918","volume":"33","author":"E Mor\u00e1n-Villase\u00f1or","year":"2019","unstructured":"Mor\u00e1n-Villase\u00f1or E, Saez-de-Ocariz M, Torrelo A, Arostegui JI, Yamazaki-Nakashimada MA, Alc\u00e1ntara-Ortigoza MA et al (2019) Expanding the clinical features of autoinflammation and phospholipase C\u03b32-associated antibody deficiency and immune dysregulation by description of a novel patient. J Eur Acad Dermatol Venereol 33(12):2334\u20132339. https:\/\/doi.org\/10.1111\/jdv.15918","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"212_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jaci.2023.08.036","volume":"153","author":"K Baysac","year":"2024","unstructured":"Baysac K, Sun G, Nakano H, Schmitz EG, Cruz AC, Fisher C et al (2024) PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants. J Allergy Clin Immunol 153(1):230\u2013242. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.036","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"212_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.02.007","volume":"153","author":"J Chinen","year":"2024","unstructured":"Chinen J (2024) Spectrum of clinical phenotypes of PLCG2 gene variants: just PLAID. J Allergy Clin Immunol S0091-6749(24)00185-4. https:\/\/doi.org\/10.1016\/j.jaci.2024.02.007","journal-title":"J Allergy Clin Immunol"},{"key":"212_CR32","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.3389\/fimmu.2019.03022","volume":"10","author":"M Christiansen","year":"2020","unstructured":"Christiansen M, Offersen R, Jensen JMB, Petersen MS, Larsen CS, Mogensen TH (2020) Identification of novel genetic variants in CVID patients with autoimmunity, autoinflammation, or malignancy. Front Immunol 10:3022. https:\/\/doi.org\/10.3389\/fimmu.2019.03022","journal-title":"Front Immunol"},{"issue":"11","key":"212_CR33","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1093\/rheumatology\/kead193","volume":"62","author":"T Itakura","year":"2023","unstructured":"Itakura T, Sasaki H, Hosoya T, Yamaguchi T, Mimori E, Saimon Y et al (2023) A novel gain-of-function missense variant in PLCG2 associated with autoinflammation and hypergammaglobulinaemia. Rheumatology (Oxford) 62(11):e319\u2013e321. https:\/\/doi.org\/10.1093\/rheumatology\/kead193","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"212_CR34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2005.01.018","volume":"22","author":"P Yu","year":"2005","unstructured":"Yu P, Constien R, Dear N, Katan M, Hanke P, Bunney TD et al (2005) Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2\u2009+\u2009entry. Immunity 22(4):451\u2013465. https:\/\/doi.org\/10.1016\/j.immuni.2005.01.018","journal-title":"Immunity"},{"issue":"5","key":"212_CR35","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/NEJMra1908213","volume":"383","author":"JA Burger","year":"2020","unstructured":"Burger JA (2020) Treatment of chronic lymphocytic leukemia. N Engl J Med 383(5):460\u2013473. https:\/\/doi.org\/10.1056\/NEJMra1908213","journal-title":"N Engl J Med"},{"issue":"1","key":"212_CR36","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250003","volume":"1","author":"MC Poli","year":"2025","unstructured":"Poli MC, Aksentijevich I, Bousfiha A, Cunningham-Rundles C, Hambleton S, Klein C et al (2025) Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. J Hum Immunol 1(1):e20250003. https:\/\/doi.org\/10.70962\/jhi.20250003","journal-title":"J Hum Immunol"},{"key":"212_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108837","volume":"231","author":"R Papa","year":"2021","unstructured":"Papa R, Rusmini M, Schena F, Traggiai E, Coccia MC, Caorsi R et al (2021) Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD). Clin Immunol 231:108837. https:\/\/doi.org\/10.1016\/j.clim.2021.108837","journal-title":"Clin Immunol"},{"issue":"7","key":"212_CR38","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2215\/CJN.0000000000000185","volume":"18","author":"C Zhang","year":"2023","unstructured":"Zhang C, Han X, Jin Y, Chen X, Gong C, Peng J et al (2023) Pathogenic gene spectrum and clinical implication in Chinese patients with lupus nephritis. Clin J Am Soc Nephrol 18(7):869\u2013880. https:\/\/doi.org\/10.2215\/CJN.0000000000000185","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"212_CR39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033221097812","volume":"31","author":"L Sun","year":"2022","unstructured":"Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H et al (2022) Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial. Lupus 31(8):998\u20131006. https:\/\/doi.org\/10.1177\/09612033221097812","journal-title":"Lupus"},{"issue":"6","key":"212_CR40","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/ard-2022-223529","volume":"82","author":"S Cai","year":"2023","unstructured":"Cai S, Hu Z, Chen Y, Chen Y, Ming B, Gao R et al (2023) BLyS\/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept. Ann Rheum Dis 82(6):881\u2013883. https:\/\/doi.org\/10.1136\/ard-2022-223529","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"212_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83(4):475\u2013487. https:\/\/doi.org\/10.1136\/ard-2023-224854","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"212_CR42","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","volume":"63","author":"D Xu","year":"2024","unstructured":"Xu D, Fang J, Zhang S, Huang C, Huang C, Qin L et al (2024) Efficacy and safety of telitacicept in primary Sjogren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology (Oxford) 63(3):698\u2013705. https:\/\/doi.org\/10.1093\/rheumatology\/kead265","journal-title":"Rheumatology (Oxford)"}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-025-00212-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-025-00212-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-025-00212-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T04:24:37Z","timestamp":1764390277000},"score":1,"resource":{"primary":{"URL":"https:\/\/molcellped.springeropen.com\/articles\/10.1186\/s40348-025-00212-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1186\/s40348-025-00212-1","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of Hunan Children\u2019s Hospital (Approval number: HCHLL-2022-10).Informed consent was obtained from the patient and her parents in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient and her parents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}